Avidity Biosciences to Participate in Upcoming Investor Conference
Avidity Biosciences Inc Ordinary Shares RNA
News
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month
Avidity Biosciences to Participate in Upcoming Investor Conferences
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock
Avidity Biosciences Announces Proposed Public Offering of Common Stock
Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights
Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in the Phase 1/2 EXPLORE44™ Trial
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity's Lead Program Gets FDA Breakthrough Designation
Avidity's stock rockets on Bristol Myers deal that could mean $2.2 billion in milestone payments
Bristol Myers Squibb to Take Stake in Avidity Biosciences, Expand Partnership
United States